Mosaic Family Wealth Partners LLC Makes New $226,000 Investment in Novo Nordisk A/S (NYSE:NVO)

Mosaic Family Wealth Partners LLC acquired a new position in shares of Novo Nordisk A/S (NYSE:NVO) during the 1st quarter, according to its most recent 13F filing with the SEC. The fund acquired 1,760 shares of the company’s stock, valued at approximately $226,000.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. Cypress Asset Management Inc. TX boosted its position in Novo Nordisk A/S by 1.2% during the 1st quarter. Cypress Asset Management Inc. TX now owns 17,916 shares of the company’s stock worth $2,392,000 after acquiring an additional 221 shares during the period. Hamilton Wealth LLC raised its position in Novo Nordisk A/S by 102.9% during the first quarter. Hamilton Wealth LLC now owns 63,856 shares of the company’s stock valued at $8,199,000 after buying an additional 32,382 shares during the period. Pathway Financial Advisers LLC acquired a new position in Novo Nordisk A/S during the first quarter valued at $34,000. Soltis Investment Advisors LLC acquired a new position in Novo Nordisk A/S during the first quarter valued at $208,000. Finally, Alexander Labrunerie & CO. Inc. purchased a new position in Novo Nordisk A/S in the first quarter valued at about $1,446,000. 11.54% of the stock is currently owned by hedge funds and other institutional investors.

Novo Nordisk A/S Stock Performance

Novo Nordisk A/S stock traded down $4.97 during midday trading on Friday, reaching $127.49. 4,774,033 shares of the company’s stock were exchanged, compared to its average volume of 3,918,008. Novo Nordisk A/S has a 52 week low of $78.19 and a 52 week high of $148.15. The firm has a market cap of $572.12 billion, a price-to-earnings ratio of 43.96, a P/E/G ratio of 1.33 and a beta of 0.41. The stock’s 50-day simple moving average is $138.21 and its 200 day simple moving average is $129.20. The company has a debt-to-equity ratio of 0.17, a quick ratio of 0.50 and a current ratio of 0.70.

Novo Nordisk A/S (NYSE:NVO) last released its quarterly earnings results on Thursday, May 2nd. The company reported $0.83 earnings per share for the quarter, beating analysts’ consensus estimates of $0.77 by $0.06. Novo Nordisk A/S had a net margin of 36.56% and a return on equity of 91.70%. The company had revenue of $9.52 billion during the quarter, compared to the consensus estimate of $9.23 billion. On average, analysts expect that Novo Nordisk A/S will post 3.38 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research analysts have commented on NVO shares. The Goldman Sachs Group started coverage on Novo Nordisk A/S in a research note on Thursday, May 30th. They issued a “buy” rating and a $156.00 target price on the stock. Argus upped their price target on Novo Nordisk A/S from $125.00 to $160.00 and gave the company a “buy” rating in a report on Monday, June 10th. Cantor Fitzgerald reissued an “overweight” rating and issued a $160.00 target price on shares of Novo Nordisk A/S in a report on Monday, July 1st. Finally, BMO Capital Markets reissued an “outperform” rating and issued a $163.00 target price on shares of Novo Nordisk A/S in a report on Tuesday, June 25th. Two equities research analysts have rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $145.67.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.